Australia-based Telix Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) to list its ordinary shares and trade on the Nasdaq under the ticker symbol “TLX.”
Telix is not proposing to raise capital or issue any new shares, it said.
The proposed Nasdaq listing is expected to be established as a Level II American Depositary Receipt (ADR) program, according to Telix. Trading of the shares is expected to take place after the SEC and Nasdaq have completed their review process and following the effectiveness of the registration statement, the company said, adding it plans to retain its primary listing for its ordinary shares on the Australian Securities Exchange (ASX) for the foreseeable future.
At the same time, Telix provided a third-quarter 2024 business update. For the quarter (end-September 30), Telix reported:
- Total revenue of approximately $135 million ($201 million AUD), primarily generated from sales of Telix’s prostate cancer imaging product Illuccix in its precision medicine (Px) business unit. The revenue represents an increase of 55% on the prior corresponding quarter (Q3 2023: $87 million ($133 million AUD).
- U.S. Illuccix sales generated $131 million ($195 million AUD).
- The company plans a business reorganization to align operations across four business units. The updated business model comprises Therapeutics, Precision Medicine (Diagnostics), Lightpoint (MedTech), and Telix Manufacturing Solutions (TMS).
The majority of Telix’s employees are now based in the U.S., the company said.
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
%20mol%20oct.0h6Wt2LMeF.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
